Eli Lilly reports its experimental drug beat Ozempic on weight loss in a Phase 3 diabetes trial. WMAR 2 Baltimore covers the results.
Recap by typeshit. Full story at WMAR 2 News Baltimore.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
A short primer on peptides as amino acid chains, noting that many wellness versions sold online lack FDA approval.
Oprah talks about how taking a GLP-1 changed the way she thinks about food noise. Tap through for her full comments.
Loading…